Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

108 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy of pembrolizumab and biomarker analysis in patients with WGS-based intermediate to high tumor mutational load: results from the Drug Rediscovery Protocol.
Geurts BS, Zeverijn LJ, Leek LVM, van Berge Henegouwen JM, Hoes LR, van der Wijngaart H, van der Noort V, van de Haar J, van Ommen-Nijhof A, Kok M, Roepman P, Jansen AML, de Leng WWJ, de Jonge MJA, Hoeben A, van Herpen CML, Westgeest HM, Wessels LFA, Verheul HMW, Gelderblom H, Voest EE. Geurts BS, et al. Among authors: van der noort v. Clin Cancer Res. 2024 Apr 17. doi: 10.1158/1078-0432.CCR-24-0011. Online ahead of print. Clin Cancer Res. 2024. PMID: 38630551
Trastuzumab plus pertuzumab for HER2-amplified advanced colorectal cancer: Results from the drug rediscovery protocol (DRUP).
Spiekman IAC, Zeverijn LJ, Geurts BS, Verkerk K, Haj Mohammad SF, van der Noort V, Roepman P, de Leng WWJ, Jansen AML, Gootjes EC, de Groot DA, Kerver ED, van Voorthuizen T, Roodhart JML, Valkenburg-van Iersel LBJ, Gelderblom H, Voest EE, Verheul HMW. Spiekman IAC, et al. Among authors: van der noort v. Eur J Cancer. 2024 May;202:113988. doi: 10.1016/j.ejca.2024.113988. Epub 2024 Mar 7. Eur J Cancer. 2024. PMID: 38471288 Free article.
Cemiplimab in locally advanced or metastatic cutaneous squamous cell carcinoma: prospective real-world data from the DRUG Access Protocol.
Verkerk K, Geurts BS, Zeverijn LJ, van der Noort V, Verheul HMW, Haanen JBAG, van der Veldt AAM, Eskens FALM, Aarts MJB, van Herpen CML, Jalving M, Gietema JA, Devriese LA, Labots M, Barjesteh van Waalwijk van Doorn-Khosrovani S, Smit EF, Bloemendal HJ. Verkerk K, et al. Among authors: van der noort v. Lancet Reg Health Eur. 2024 Mar 5;39:100875. doi: 10.1016/j.lanepe.2024.100875. eCollection 2024 Apr. Lancet Reg Health Eur. 2024. PMID: 38464480 Free PMC article.
Combined Cabazitaxel and Carboplatin Treatment of Metastatic Castration Resistant Prostate Cancer Patients, With Innate or Acquired Resistance to Cabazitaxel Monotherapy.
van der Zande K, Tutuhatunewa-Louhanepessy RD, Hamberg P, Ras S, de Feijter JM, Dezentjé VO, Broeks A, Cornelissen S, Beeker A, van der Noort V, Zwart W, Bergman AM. van der Zande K, et al. Among authors: van der noort v. Clin Genitourin Cancer. 2024 Apr;22(2):445-453.e1. doi: 10.1016/j.clgc.2023.12.016. Epub 2024 Jan 3. Clin Genitourin Cancer. 2024. PMID: 38246830 Free article.
Efficacy and Safety of Panitumumab in Patients With RAF/RAS-Wild-Type Glioblastoma: Results From the Drug Rediscovery Protocol.
Spiekman IAC, Geurts BS, Zeverijn LJ, de Wit GF, van der Noort V, Roepman P, de Leng WWJ, Jansen AML, Kusters B, Beerepoot LV, de Vos FYFL, de Groot DA, de Groot JWB, Hoeben A, Buter J, Gelderblom HAJ, Voest EE, Verheul HMW. Spiekman IAC, et al. Among authors: van der noort v. Oncologist. 2024 May 3;29(5):431-440. doi: 10.1093/oncolo/oyad320. Oncologist. 2024. PMID: 38109296 Free PMC article.
Nivolumab and ipilimumab in the real-world setting in patients with mesothelioma.
Dumoulin DW, Douma LH, Hofman MM, van der Noort V, Cornelissen R, de Gooijer CJ, Burgers JA, Aerts JGJV. Dumoulin DW, et al. Among authors: van der noort v. Lung Cancer. 2024 Jan;187:107440. doi: 10.1016/j.lungcan.2023.107440. Epub 2023 Dec 14. Lung Cancer. 2024. PMID: 38104353 Free article.
Pembrolizumab plus lenvatinib in second-line and third-line patients with pleural mesothelioma (PEMMELA): a single-arm phase 2 study.
Douma LH, Lalezari F, van der Noort V, de Vries JF, Monkhorst K, Smesseim I, Baas P, Schilder B, Vermeulen M, Burgers JA, de Gooijer CJ. Douma LH, et al. Among authors: van der noort v. Lancet Oncol. 2023 Nov;24(11):1219-1228. doi: 10.1016/S1470-2045(23)00446-1. Epub 2023 Oct 13. Lancet Oncol. 2023. PMID: 37844598 Clinical Trial.
108 results